The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC).
Daniel H. Palmer
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - Boehringer Ingelheim
Markus Peck-Radosavljevic
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim
Yuk Ting Ma
No relevant relationships to disclose
Janet Graham
No relevant relationships to disclose
Laetitia Fartoux
No relevant relationships to disclose
Richard Hubner
Consultant or Advisory Role - Novartis
Arsene Bienvenu Loembe
Employment or Leadership Position - Boehringer Ingelheim
Matus Studeny
Employment or Leadership Position - Boehringer Ingelheim
Julia Hocke
Employment or Leadership Position - Boehringer Ingelheim
Tim Meyer
No relevant relationships to disclose